-
Convergence of US FDA & Drug Pricing
Written by
The FDA, under new leadership, is taking an unprecedented role in drug pricing by linking approval incentives—like Priority Vouchers—to economic impact and Most Favored Nation (MFN) pricing. This blurs the traditional separation between regulatory review and payer negotiation, pressuring prices from day one. These shifts could reshape biopharma valuations, launch strategies, and access dynamics. Companies must closely track policy changes and strengthen development plans that demonstrate meaningful clinical and economic value.
